JP6955632B2 - 製剤 - Google Patents

製剤 Download PDF

Info

Publication number
JP6955632B2
JP6955632B2 JP2020527951A JP2020527951A JP6955632B2 JP 6955632 B2 JP6955632 B2 JP 6955632B2 JP 2020527951 A JP2020527951 A JP 2020527951A JP 2020527951 A JP2020527951 A JP 2020527951A JP 6955632 B2 JP6955632 B2 JP 6955632B2
Authority
JP
Japan
Prior art keywords
antibody
formulations
pharmaceutical composition
antigen
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020527951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504321A (ja
JP2021504321A5 (https=
Inventor
デュラン、サンドリーヌ
ジェフリー イェーツ、アンドリュー
ジェフリー イェーツ、アンドリュー
Original Assignee
ユーシービー バイオファルマ エスアールエル
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル, ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2021504321A publication Critical patent/JP2021504321A/ja
Publication of JP2021504321A5 publication Critical patent/JP2021504321A5/ja
Application granted granted Critical
Publication of JP6955632B2 publication Critical patent/JP6955632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020527951A 2017-11-23 2018-11-13 製剤 Active JP6955632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1719447.3A GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition
GB1719447.3 2017-11-23
PCT/EP2018/081129 WO2019101582A1 (en) 2017-11-23 2018-11-13 Formulation

Publications (3)

Publication Number Publication Date
JP2021504321A JP2021504321A (ja) 2021-02-15
JP2021504321A5 JP2021504321A5 (https=) 2021-07-26
JP6955632B2 true JP6955632B2 (ja) 2021-10-27

Family

ID=60950516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020527951A Active JP6955632B2 (ja) 2017-11-23 2018-11-13 製剤

Country Status (19)

Country Link
US (2) US11857625B2 (https=)
EP (1) EP3713602A1 (https=)
JP (1) JP6955632B2 (https=)
KR (1) KR102767553B1 (https=)
CN (1) CN111511399A (https=)
AR (1) AR113534A1 (https=)
AU (1) AU2018371056B2 (https=)
BR (1) BR112020009866A2 (https=)
CA (1) CA3082832C (https=)
CL (1) CL2020001307A1 (https=)
CO (1) CO2020006120A2 (https=)
EA (1) EA202091295A1 (https=)
GB (1) GB201719447D0 (https=)
IL (1) IL274719B2 (https=)
MX (1) MX2020004747A (https=)
MY (1) MY194682A (https=)
RU (1) RU2020120547A (https=)
SG (1) SG11202004601YA (https=)
WO (1) WO2019101582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
SG10201510762YA (en) * 2011-01-14 2016-01-28 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
PE20150190A1 (es) * 2012-06-21 2015-02-13 Ucb Pharma Sa Formulacion farmaceutica
CN107148283A (zh) * 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
MY206805A (en) 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
US20190060241A1 (en) 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
KR102329490B1 (ko) 2016-09-14 2021-11-23 베이징 한미 파마슈티컬 컴퍼니 리미티드 Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편

Also Published As

Publication number Publication date
BR112020009866A2 (pt) 2020-11-17
AU2018371056A1 (en) 2020-06-04
MY194682A (en) 2022-12-14
CA3082832A1 (en) 2019-05-31
JP2021504321A (ja) 2021-02-15
CA3082832C (en) 2023-07-18
EA202091295A1 (ru) 2020-09-03
EP3713602A1 (en) 2020-09-30
AR113534A1 (es) 2020-05-13
AU2018371056B2 (en) 2024-06-20
CO2020006120A2 (es) 2020-05-29
IL274719A (en) 2020-07-30
WO2019101582A1 (en) 2019-05-31
RU2020120547A (ru) 2021-12-23
GB201719447D0 (en) 2018-01-10
US11857625B2 (en) 2024-01-02
KR20200090829A (ko) 2020-07-29
MX2020004747A (es) 2020-08-20
US20210106683A1 (en) 2021-04-15
KR102767553B1 (ko) 2025-02-12
RU2020120547A3 (https=) 2021-12-23
CL2020001307A1 (es) 2020-10-16
IL274719B1 (en) 2024-06-01
US20240123065A1 (en) 2024-04-18
SG11202004601YA (en) 2020-06-29
CN111511399A (zh) 2020-08-07
IL274719B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
JP6955632B2 (ja) 製剤
RU2704838C1 (ru) СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
AU2011227335B2 (en) Anti-nerve growth factor (NGF) antibody compositions
JP7126454B2 (ja) 医薬組成物
TWI433685B (zh) 經修飾之單域抗原結合分子及其用途
JP6769879B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む液体製剤
US20240309080A1 (en) Pharmaceutical composition containing anti-tslp antibody
MX2014015262A (es) Formulacion de anticuerpos.
US20190083617A1 (en) Pharmaceutical formulations
TWI639440B (zh) 包括ｇｍ－ｃｓｆ中和化合物之液態配方
JP6339578B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
EA035719B1 (ru) Фармацевтический состав
JP7608173B2 (ja) 高濃度液体抗体製剤
CN119907808A (zh) 抗tl1a抗体配制品
EA041921B1 (ru) Фармацевтическая композиция
HK40003145A (en) Pharmaceutical formulation comprising antibody, cyclodextrin and methionine
HK40003145B (en) Pharmaceutical formulation comprising antibody, cyclodextrin and methionine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210531

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211001

R150 Certificate of patent or registration of utility model

Ref document number: 6955632

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220622

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153